Back to Missouri

SB1569 • 2026

Creates new provisions relating to insurance coverage for treatment of certain menopause-related conditions

Creates new provisions relating to insurance coverage for treatment of certain menopause-related conditions

Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor
Lewis, Patty; House handler: N/A
Last action
2026-02-05
Official status
Second Read and Referred S Insurance and Banking Committee
Effective date
2026-08-28

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

Creates new provisions relating to insurance coverage for treatment of certain menopause-related conditions

The following summaries of this bill are available: Print All Summaries Introduced Print SB 1569 - This act requires health benefit plans delivered, issued for delivery, continued, or renewed in this state on or after January 1, 2027, to provide coverage for the treatment of perimenopause, menopause, and post-menopause, as described in the act.

What This Bill Does

  • The following summaries of this bill are available: Print All Summaries Introduced Print SB 1569 - This act requires health benefit plans delivered, issued for delivery, continued, or renewed in this state on or after January 1, 2027, to provide coverage for the treatment of perimenopause, menopause, and post-menopause, as described in the act.
  • The coverage shall be limited to those drugs and medications that have been approved by the U.S.
  • Food and Drug Administration and shall not be subject to any greater deductible or co-payment than other similar health care services provided by the health benefit plan.
  • TAYLOR MIDDLETON

Limits and Unknowns

  • This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

  1. 2026-02-05 S309

    Second Read and Referred S Insurance and Banking Committee

  2. 2026-01-20 S201

    S First Read

Official Summary Text

The following summaries of this bill are available:

Print All Summaries

Introduced

Print

SB 1569 - This act requires health benefit plans delivered, issued for delivery, continued, or renewed in this state on or after January 1, 2027, to provide coverage for the treatment of perimenopause, menopause, and post-menopause, as described in the act. The coverage shall be limited to those drugs and medications that have been approved by the U.S. Food and Drug Administration and shall not be subject to any greater deductible or co-payment than other similar health care services provided by the health benefit plan.
TAYLOR MIDDLETON

Current Bill Text

Read the full stored bill text
SECOND REGULAR SESSION
SENATE BILL NO. 1569
103RD GENERAL ASSEMBLY
INTRODUCED BY SENATOR LEWIS.
6300S.01I KRISTINA MARTIN, Secretary
AN ACT
To amend chapter 376, RSMo, by adding thereto one new section relating to insurance coverage
for treatment of certain menopause-related conditions.
Be it enacted by the General Assembly of the State of Missouri, as follows:
Section A. Chapter 376, RSMo, is amended by adding thereto 1
one new section, to be known as section 376.1243, to read as 2
follows:3
376.1243. 1. Each health carrier or health benefit 1
plan that offers or issues health benefit plans that are 2
delivered, issued for delivery, continued, or renewed in 3
this state on or after January 1, 2027, shall provide 4
coverage for the treatment of perimenopause, menopause, and 5
postmenopause, including, but not limited to, the following: 6
(1) Hormone therapy, including, but not limited to, 7
combined estrogen and hormone medicines, combination 8
estrogen and progesterone medicines, and estrogen-only 9
medicines; 10
(2) Selective serotonin reuptake inhibitors (SSRIs) 11
and serotonin-norepinephrine reuptake inhibitors (SNRIs); 12
(3) Vaginal estrogen; 13
(4) Medications to prevent or treat osteoporosis; 14
(5) Neurokinin B antagonists; 15
(6) Topical hormone therapy; and 16
(7) Bioidentical hormones. 17
SB 1569 2
2. The coverage provided under this section shall be 18
limited to those drugs and medications that have been 19
approved by the U.S. Food and Drug Administration. 20
3. The coverage required under this section shall not 21
be subject to any greater deductible or copayment than other 22
similar health care services provided by the health benefit 23
plan. 24
4. The provisions of this section shall not apply to a 25
supplemental insurance policy, including a life care 26
contract, accident-only policy, specified disease policy, 27
hospital policy providing a fixed daily benefit only, 28
Medicare supplement policy, long-term care policy, short- 29
term major medical policies of six months' or less duration, 30
or any other supplemental policy as determined by the 31
director of the department of commerce and insurance. 32
✓